- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Torvutatug samrotecan, Bevacizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Baltimore, Maryland • Billings, Montana + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 1,902
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis, Renal Impairment
- Interventions
- fostamatinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
- Interventions
- Vactosertib(TEW-7197)/ Durvalumab
- Drug
- Lead sponsor
- MedPacto, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Buffalo, New York
- Conditions
- Atrial Fibrillation
- Interventions
- dapagliflozin, Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Portland, Maine • Detroit, Michigan • Rochester, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Saxagliptin, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- ER+ HER2- Advanced Breast Cancer
- Interventions
- AZD9496
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • New York, New York • Nashville, Tennessee
- Conditions
- Breast Neoplasms
- Interventions
- Gefitinib, Tamoxifen
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 4
- States / cities
- Berkeley, California • Palm Springs, California • St Louis, Missouri + 1 more
- Conditions
- Treatment Resistant Major Depressive Disorder
- Interventions
- AZD6765, Placebo to AZD6765
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 58
- States / cities
- Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more
- Conditions
- Transthyretin Cardiac Amyloidosis
- Interventions
- Not listed
- Lead sponsor
- Idoven 1903 S.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
- Interventions
- Tezepelumab, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
- Conditions
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
- Interventions
- AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Santa Rosa, California • West Hills, California + 10 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Osimertinib, SABR
- Drug · Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Dallas, Texas
- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD8359
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Orlando, Florida • East Brunswick, New Jersey • Hackensack, New Jersey + 1 more
- Conditions
- Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ophthalmic Safety in Patients With Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- La Jolla, California • Palo Alto, California • Iowa City, Iowa + 6 more
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin Tablet, Placebo Tablet
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
- Interventions
- Vigil, Durvalumab
- Biological · Drug
- Lead sponsor
- Mary Crowley Medical Research Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years to 80 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cardiovascular Disease
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,836 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Brentwood, Tennessee
- Conditions
- Mesothelioma
- Interventions
- Tremelimumab, Durvalumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 15
- States / cities
- Monterey, California • Santa Rosa, California • Colorado Springs, Colorado + 12 more
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware